EXOZYMES INC

EXOZNASDAQ

🏆 #3578 by market capUS Equity

$4.79▼ $1.10 (−22.99%)

Market closed · at close

1h—

24h▼ 23.0%

7d▲ 0.0%

14d▼ 23.0%

30d▼ 41.6%

1y▼ 51.5%

🏦Market Cap

$44M

Small Cap

📈Revenue Growth (YoY)

—

📊Gross Margin

—

💵FCF Margin

—

⚖️P/S Ratio

—

Otter Score

Fair

Trading Snapshot

Day Range: $4.77 – $4.84
52-Week Range: $4.35 – $18.40
Volume: $3.27B
Avg Volume: $3.42B
Shares Outstanding: 9.3M
Next Earnings: Oct 14, 2026

Fundamentals Snapshot

Annual Revenue: $3M
Last Q Revenue: $762,355
P/E Ratio: —
P/S Ratio: —
EPS (TTM): $-1.15
Dividend Yield: —

Why Investors Own EXOZ

✓High-growth profile — revenue up -7.3% YoY with expanding US Equity exposure.
✓Healthy economics — 65% gross margin and 12% free-cash-flow margin.
✓New products and segments could unlock additional revenue streams.

⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

Financial Trends

Revenue (TTM)

$3M▼ −5.2% YoY

Gross Margin (TTM)

64.9%▲ +1.4% YoY

Operating Income (TTM)

$800,691▼ −5.2% YoY

Free Cash Flow (TTM)

$353,330▼ −5.2% YoY

About EXOZYMES INC

eXoZymes, Inc. operates as a development stage biotechnology company. It focuses on the development of enzyme modules and cell-free exozyme biosolutions for synthetic biology manufacturing. The company was formerly known as Invizyne Technologies, Inc. and changed its name to eXoZymes, Inc. in February 2025. eXoZymes, Inc. was incorporated in 2014 and is headquartered in Monrovia, California.

🦦